Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity |
| |
| Affiliation: | 1. Department of Cardiology, Shanghai Ninth People''s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People''s Republic of China;2. Department of Cardiology, Shanghai Minhang Hospital, Fudan University, Shanghai, People''s Republic of China;1. Section of Cardiovascular Medicine, VA Connecticut, West Haven, Connecticut;2. Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut;3. Western University of Health Sciences, Pomona, California;4. Veterans Affairs Medical Center, Minneapolis, Minnesota;5. University of Minnesota, Minneapolis, Minnesota;6. CCRE Therapeutics, Monash University, Melbourne, Australia;7. Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts;8. British Heart Foundation Glasgow Cardiovascular Research Center, Glasgow, United Kingdom;9. RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina;10. Université Paris 6; Pitie Salpetriere Hospital, Paris, France;11. Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada;12. Washington VAMC and Georgetown University, Washington, DC;1. Department of Pharmaceutical Chemistry, University of Athens School of Pharmacy, Athens, Greece;2. First Department of Surgery, University of Athens Medical School, Athens, Greece;3. Department of Cardiology, Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece;4. Second Department of Cardiology, University of Athens Medical School, Attikon University Hospital, Athens, Greece;5. First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece;6. Department of Nutrition and Dietetics, Harokopio University, Athens, Greece;7. Department of Pathology, University of Athens Medical School, Athens, Greece |
| |
| Abstract: | Resveratrol (RSV) has many biological effects, including antitumor and antiviral activities, and vascular protection. Recent studies have suggested that RSV exerts its antitumor effects through induction of autophagy by an unknown mechanism. Doxorubicin (DOX) is a wide spectrum antitumor drug, but its clinical application is limited by its cardiotoxicity. This study evaluated whether the manipulation of autophagy could attenuate the cardiotoxic effects of DOX in vitro as well as in a rat model of DOX-induced cardiotoxicity. We found that DOX induced H9C2 cell apoptosis by inhibiting AMPK activation and promoting pro-apoptotic protein expression through p38MAPK/p53 signaling. RSV-treated H9C2 cells showed increased autophagy through the AMPK/mTOR/Ulk1 pathway. When DOX and RSV were combined, apoptosis was decreased, despite a slight increase in the autophagy ratio. The same result was observed in the rat model of DOX-induced cardiotoxicity. Injection with DOX or RSV alone, or in combination, for a week, resulted in a reduced apoptotic ratio in the combination group compared with the DOX alone group. Our results strongly indicate that this co-treatment strategy with RSV can attenuate the cardiotoxic effects of DOX. Our findings may have important clinical implications. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
